Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 4/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469305 | 0.87 | ABL1 (0.34) | ABL1BRAFIRAK4ATR | |
| SCHEMBL26112581 | 0.85 | EGFR (0.36) | EGFRHCRTR1HCRTR2BRAF | |
| SCHEMBL26113701 | 0.83 | IRAK4 (0.36) | EGFRBTKHCRTR1HCRTR2MAPT | |
| SCHEMBL30590886 | 0.83 | EGFR (0.35) | EGFRHCRTR1HCRTR2BRAF | |
| SCHEMBL26115718 | 0.80 | NPC1 (0.41) | EGFRBTK | |
| SCHEMBL26114453 | 0.80 | EGFR (0.37) | ABL1EGFRBTKHCRTR1HCRTR2 | |
| SCHEMBL30591045 | 0.80 | EGFR (0.37) | ABL1EGFRBTKHCRTR1HCRTR2 | |
| SCHEMBL26114411 | 0.79 | JAK2 (0.37) | EGFRHCRTR1HCRTR2BRAF | |
| SCHEMBL30590893 | 0.79 | AURKA (0.32) | EGFRHCRTR1HCRTR2BRAF | |
| SCHEMBL26111504 | 0.79 | GPR6 (0.34) | EGFRIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ABL1 5/4885EGFR 1/4885BTK 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.